Is the UK public ready for genetic medicine?

While discussion about the potential for personalized medicine persists, in the UK embedding pharmacogenetics in mainstream clinical practice will also depend on high levels of confidence and trust of citizens in the motives of stakeholders. The role of Government, regulators and the guidance offered by health practitioners will contribute to its acceptance or otherwise. Nowgen, a center for genetics in healthcare, is dedicated to exploring how health service research, practice and innovation, in relation to genetic medicine, are informed and perceived by the public.

Oral oxymorphone for pain management.

Objective: To describe the pharmacology, safety and efficacy, and rationale for use of oral oxymorphone for the management of acute and chronic moderate-to-severe pain.

Data Sources: A PubMed/MEDLINE search (1966-March 2007) was conducted using the following terms: oral oxymorphone, oxymorphone, EN 3202, EN 3203, Opana, and Opana ER. Manufacturer-provided data (package inserts) and abstracts presented at the American Pain Society meetings (2003-2006) were also reviewed.